Iodoxamic Acid

Summary

Iodoxamic Acid (CHEMBL1615487) is an approved small molecule (ATC V08AC01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AC01
• Chemistry: 1287.9 Da · C26H26I6N2O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1615487
Name	Iodoxamic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	35740
ATC	V08AC01
Molecular formula	C26H26I6N2O10
Molecular weight	1287.9
InChIKey	WWVAPFRKZMUPHZ-UHFFFAOYSA-N

SMILES: C1=C(C(=C(C(=C1I)NC(=O)CCOCCOCCOCCOCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I

IUPAC name: 3-[3-[2-[2-[2-[3-(3-carboxy-2,4,6-triiodoanilino)-3-oxopropoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-2,4,6-triiodobenzoic acid

Also known as: Acide iodoxamique, Acido iodoxamico, B 10610, B-10610, Endobil, Endomirabil, Iodoxamic acid, Iodoxamid, SQ 21982, SQ-21982, Videocolangio, IODOXAMIC ACID

Parent form; salt/anhydrous children: CHEMBL4594231

Patent coverage: 65 distinct patent families (127 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).